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Abstract
Chronic mTORc1 hyperactivation via obesity-induced hyperleucinaemia has been implicated in the development of insulin 
resistance, yet the direct impact of leucine on insulin-stimulated glucose uptake in muscle cells remains unclear. To address 
this, differentiated L6 myotubes were subjected to various compounds designed to either inhibit mTORc1 activity (rapa-
mycin), blunt leucine intracellular import (BCH), or activate mTORc1 signalling (3BDO), prior to the determination of the 
uptake of the glucose analogue, 2-deoxyglucose (2-DG), in response to 1 mM insulin. In separate experiments, L6 myotubes 
were subject to various media concentrations of leucine (0–0.8 mM) for 24 h before 2-DG uptake in response to insulin was 
assessed. Both rapamycin and BCH blunted 2-DG uptake, irrespective of insulin administration, and this occurred in parallel 
with a decline in mTOR, 4E-BP1, and p70S6K phosphorylation status, but little effect on AKT phosphorylation. In contrast, 
reducing leucine media concentrations suppressed 2-DG uptake, both under insulin- and non-insulin-stimulated conditions, 
but did not alter the phosphorylation state of AKT-mTORc1 components examined. Unexpectedly, 3BDO failed to stimulate 
mTORc1 signalling, but, nonetheless, caused a significant increase in 2-DG uptake under non-insulin-stimulated conditions. 
Both leucine and mTORc1 influence glucose uptake in muscle cells independent of insulin administration, and this likely 
occurs via distinct but overlapping mechanisms.
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Introduction
The global incidence of diabetes continues to increase una-
bated, with 451 million adults in 2017 estimated to have 
the condition, a number that is expected to increase to 693 
million by 2045 (Cho et al. 2018). In attempting to deline-
ate the aetiology of type-2 diabetes mellitus (T2DM) which 
accounts for the majority of cases, it has been proposed that 
chronic increases in circulating concentrations of branched 
chain amino acids (BCAA) could contribute to the impaired 
ability of insulin to stimulate peripheral glucose disposal 
in these patients (Newgard et al. 2009). Notably, increased 
blood concentrations of BCAA have been observed in both 
insulin resistant and obese individuals (Caballero et al. 1988; 
Felig et al. 1969), with the concentrations of various BCAA-
related metabolites showing a significant linear relationship 
with measures of insulin resistance in humans (Newgard 
et al. 2009). Moreover, in animal models of obesity, the 
genetic or pharmacological manipulation of the branched 
chain ketoacid dehydrogenase complex so as to aid clearance 
of circulating BCAAs via increased hepatic uptake causes 
improvements in both insulin sensitivity and glucose toler-
ance (White et al. 2018).
BCAA, in particular the amino acid leucine, are widely 
known to induce profound metabolic effects on skeletal mus-
cle, a major site of glucose disposal in the body. Leucine is a 
potent stimulator of protein synthesis within muscle cells, a 
process achieved through activation of the kinase mamma-
lian target of rapamycin (mTORc1), which, in turn, drives 
translation initiation as a consequence of the phosphoryla-
tion of downstream targets 4E-BP1 and p70S6K (see Mur-
ton et al. 2008). In recent years, it has also been suggested 
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that mTORc1 is able to phosphorylate upstream targets of 
the insulin signalling pathway in muscle, leading to inhibi-
tion of the pathway, and in turn impaired translocation of 
the GLUT4 glucose transporter to the plasma membrane 
(Yoneyama et al. 2018). Thus, it has been proposed that a 
potential mechanism by which obesity-induced increases in 
blood BCAA concentrations could lead to the development 
of insulin resistance is through the chronic activation of 
mTORc1 suppressing insulin signalling in skeletal muscle.
In contrast to this purported mechanism, we have found 
that muscle mTORc1 signalling and its response to exog-
enous amino acids is not impaired in obese men, despite 
clear evidence for the presence of insulin resistance (Mur-
ton et al. 2015). Likewise, it has been reported that both 
acute and chronic systemic inhibition of mTORc1 function 
induces insulin resistance in rodents (Deblon et al. 2012; 
Kleinert et al. 2014), and the administration of leucine or 
mixed amino acids can increase insulin-stimulated glucose 
uptake (Kleinert et al. 2011; Li et al. 2013). In light of these 
findings, debate remains surrounding the contribution of 
BCAA-stimulated mTORc1 hyperactivation in the patho-
physiology of peripheral insulin resistance.
A potential explanation for the discord between findings 
to date is the challenge associated with studying the impact 
of amino acids on tissue metabolism in vivo. As noted by 
others (White and Newgard 2019), supplementing with indi-
vidual amino acids or manipulating systemic mTORc1 func-
tion also impacts metabolism in distal tissues, potentially 
underpinning the inconsistent observations seen between 
studies. Thus, to circumvent these issues, the aim of the 
current study was to delineate the role of leucine on glucose 
uptake in cultured muscle cells, utilizing multiple strategies 
to manipulate leucine availability and mTORc1 function so 




Culture media (high-glucose Dulbecco’s Modified Eagle’s 
Media, DMEM), 3BDO, and BCH were obtained from 
Sigma-Aldrich (Poole, UK.) DMEM without glucose and 
l-leucine was ordered from Cell Culture Technologies 
(Ticino, Switzerland). l-leucine free medium (DMEM-
LM, 30,030) and horse serum were ordered from Thermo 
Fisher (Loughborough, UK). Heat inactivated Fetal bovine 
serum (FBS) and Penicillin/Streptomycin were obtained 
from Gibco by Life technologies (Loughborough, UK). 
Rapamycin was purchased from Cell Signalling Technolo-
gies (London, UK). Antibodies: rabbit anti mTOR antibody 
(#2972), rabbit anti-phospho-mTOR (Ser2448; #2971), 
rabbit anti-phospho-4E-BP1 (Thr37/46; #9459), rabbit 
anti-4E-BP1 (#9452), rabbit anti-phospho-p70 S6 Kinase 
(Thr389; #9205), rabbit anti-p70 S6 Kinase (#9202), rabbit 
anti-phospho-Akt (Ser473, #9271), rabbit anti-Akt (#9272), 
rabbit anti-β-Actin Antibody (#4967), anti-rabbit IgG, and 
HRP-linked Antibody (#7074) were all purchased from Cell 
Signalling Technologies (London, UK). Glucose Uptake-
Glo™ Assay kit was purchased from Promega (Southamp-
ton, UK).
Cell culture
L6 myoblasts were cultured in growth medium consisting of 
high-glucose Dulbecco’s Modified Eagle Media (DMEM), 
supplemented with 10% (v/v) fetal bovine serum, and 1% 
(v/v) penicillin and streptomycin, until approximately 
70–80% confluent. High-glucose DMEM was utilized in 
response to our observations that L6 cells cultured under 
low-glucose DMEM (5.6 mM) failed to demonstrate robust 
uptake of the glucose analogue 2-deoxyglucose, in response 
to 100 mM insulin administration (data not shown). After 
the L6 myoblasts had reached the required level of conflu-
ence, they were switched to differentiation medium consist-
ing of DMEM supplemented with 2% (v/v) horse serum and 
1% (v/v) penicillin and streptomycin, causing the formation 
of myotubes. The day that L6 myoblasts were switched to 
differentiation media was labelled as ‘day 0’, and differentia-
tion media were replaced every 2 days.
At days 5 or 6, a time period which we have shown suf-
ficient to induce myotube formation (Hurley et al. 2006), 
the differentiation media were removed and replaced with 
fresh DMEM containing 1% (v/v) penicillin and strepto-
mycin but devoid of serum. Cells were maintained under 
the serum starvation protocol for 24 h before the impact 
of various investigatory drugs studied. To investigate the 
impact of mTORc1 function on glucose uptake, rapamycin 
(100 nM), or 3-Benzyl-5-((2-nitrophenoxy)methyl)-dihydro-
furan-2(3H)-one (3BDO; 60 µM), both initially dissolved 
in dimethylsulfoxide (DMSO), were administered to myo-
tubes for a period of 1 (rapamycin only) or 4 h (both) to 
either inhibit or stimulate mTORc1 activity, respectively, 
and compared to controls also containing 1.2% DMSO. In 
separate experiments, to establish the direct impact of leu-
cine on insulin-stimulated glucose uptake, myotubes were 
treated following 24 h serum starvation with either the non-
metabolizable leucine analogue, b(-)2-amino-bicyclo[2,2,1]
heptane-2-carbocyclic acid (BCH; 25  mM) or leucine 
(0–0.8 mM, where 0.8 mM represents the leucine concentra-
tion of standard DMEM), with both dissolved in the media 
and administered for 4 or 24 h, respectively.
After their respective treatments, the subsequent impact 
of the various compounds and leucine concentrations on 
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insulin-stimulated glucose uptake and mTORc1 signalling 
were assessed as described below.
Glucose uptake assay
Glucose uptake in L6 myotubes was assessed using a com-
mercial kit that involves the determination of 2-deoxyglu-
cose-6-phosphate (2DG6P) concentrations in cells following 
2-deoxyglucose administration. In short, following treatment 
with the test compound, half of the treated wells were incu-
bated at 37 °C for 1 h in the presence of 1 mM insulin. 
After the allotted time, the media were removed and the cells 
were washed in PBS, followed by the addition of 0.1 mM 
2-deoxyglucose in PBS to all wells. Cells were incubated for 
30 min at 25 °C, after which 2DG6P concentrations were 
measured according to the manufacturer’s instructions using 
a luminescence plate reader (Fluostar, Omega).
Intracellular free branched chain amino acid (BCAA) 
concentrations
A commercial colorimetric assay kit for the determination of 
BCAA concentrations was utilized to assess free intracellu-
lar BCAA concentrations (BioVision). Following treatment 
with the test compound, cells were collected in 50 µl of assay 
buffer and subsequently lysed by sonication for 10–15 s. 
Afterwards, samples were centrifuged at 14,000 rpm for 
10 min at 4 °C to remove cellular debris and other insoluble 
material. 20 µl of the resultant supernatant which contained 
the intracellular free amino acids was diluted to 50 µl with 
assay buffer and analysed according to the manufacturer’s 
instructions, with the resultant colour product detected using 
a microplate reader set at a wavelength of 450 nm (Fluostar, 
Omega). The concentration obtained through use of this 
approach equated to the sum of the concentration of the three 
individual BCAA: leucine, isoleucine, and valine.
Western blot analysis
To establish the impact of the various treatments on 
mTORc1 signalling, L6 myotubes grown in 6-well plates 
were lysed at the end of the treatment with the test com-
pound using ice-cold lysis buffer (20% v/v glycerol, 12.5% 
v/v 1 M Tris–HCL (pH 6.8), 4% w/v SDS, 10% 1 M DTT, 
and 0.004% w/v bromophenol blue), containing both phos-
phatase and protease inhibitors (Roche). Protein concen-
trations were determined using the commercial 2D Quant 
kit (GE Healthcare Life Sciences, Buckinghamshire, UK) 
and samples adjusted to a constant final concentration of 1 
or 2 μg/μl (dependent upon experiment) using lysis buffer. 
Afterwards, 15 μl of each sample was separated by elec-
trophoresis on a 4–15% SDS-PAGE gel and transferred to 
PVDF membranes (GE Healthcare) using the established 
techniques (Murton et al. 2009). Afterwards, membranes 
were blocked by incubating in 5% (w/v) bovine serum albu-
min (BSA). The abundance and phosphorylation state of 
individual proteins were assessed using commercial primary 
antibodies diluted 1:1000 in 5% w/v BSA, HRP-linked sec-
ondary antibody diluted 1:5000 with 5% w/v BSA, and visu-
alized by enhanced chemiluminescence (ECL; GE Health-
care, Buckinghamshire, UK). When determining both the 
degree of phosphorylation and total protein abundance of the 
same target protein, the membrane was first probed by use of 
the phosphorylation-specific antibody, before being stripped 
with a commercial stripping buffer (Thermo Fisher), and 
re-probed with the non-phosphorylation specific version of 
the antibody. Blots were analysed using the ChemiDoc MP 
Imaging System (Bio-Rad, CA, USA) and associated Image 
Lab 6.0.1 Software (Bio-Rad, CA, USA).
Statistics
Except where stated, when considering the effect of insulin 
and rapamycin on 2-deoxyglucose uptake and mTORc1 sig-
nalling (Fig. 1), a two-way ANOVA was performed to test 
for statistical significance. In all other cases, insulin- and 
non-insulin-stimulated experiments were performed in sepa-
rate batches, and as such data were analysed by use of a one-
way ANOVA statistical test. All statistical tests were per-
formed using the software, Prism (v 8.2.0, GraphPad). When 
a significant main effect was observed (one-way ANOVA) 
or interaction (two-way ANOVA), a post hoc test (Tukey) 
was performed to identify statistically significant differences 
between groups. A value of p < 0.05 was considered statis-
tically significant. Data are presented as means ± standard 
error of the mean (SEM).
Results
Rapamycin‑induced inhibition of mTORc1 signalling 
blun
ts glucose uptake in L6 myotubes, irrespective 
of insulin administration
It has previously been shown that a discordance exists in 
the ability of insulin to stimulate glucose uptake in muscle 
cell lines of murine and rodent origin (Sarabia et al. 1990). 
Thus, to confirm that the cultured L6 myotubes are sensitive 
to the actions of insulin and represent an appropriate model 
to investigate glucose uptake in muscle cells, L6 myotubes 
were administered 100 nM insulin, a dose known to induce 
robust increases in glucose uptake (Yap et al. 2007). Treat-
ment with insulin for 1 h resulted in a doubling in the uptake 
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of the glucose analogue compared to control, confirming the 
suitability of this model (Fig. 1a, p < 0.001, unpaired t test).
Next, to confirm the effect of insulin administration on 
mTORc1 signalling, and to ascertain whether mTORc1 
activity in part contributes to insulin-dependent glucose 
uptake in muscle cells, mTORc1 activity was blunted using 
the established inhibitor, rapamycin, at a concentration 
known to inhibit mTORc1 signalling (Deblon et al. 2012). 
This was performed under both insulin and non-insulin-
stimulated conditions. As expected, insulin administration 
resulted in significant increases in the phosphorylation state 
of mTOR and its downstream targets 4E-BP1 and p70S6K 
(main effect of insulin: p < 0.001; Fig. 1b–d and f), while 
treatment with 100 nM rapamycin for 1 h induced decreased 
phosphorylation of mTOR and its downstream targets, irre-
spective of insulin treatment (p < 0.05; Fig. 1b–d). Likewise, 
rapamycin treatment blunted the ability of insulin to stimu-
late uptake of the glucose analogue by 52%, which persisted 
even when the period of rapamycin treatment was extended 
by a further 3 h (Fig. 1e). Collectively, these findings suggest 
that the dose of rapamycin utilized in these experiments was 
effective at impairing insulin-stimulated mTORc1 signalling 
and resulted in a blunted ability of insulin to induce cellular 
glucose uptake. Somewhat unexpectedly, a similar, albeit 
more modest ability of rapamycin to suppress mTORc1 sig-
nalling and 2-deoxyglucose uptake was also observed in the 
absence of insulin (Fig. 1b–e).
BCH significantly impairs the ability of insulin 
to stimulate mTORc1 signalling and 2‑deoxyglucose 
uptake in L6 myotubes, independent of insulin 
signalling
Inhibiting the action of mTORc1, even transiently, is known 
to lead to an increase in intracellular amino acid concen-
trations due to decreased sequestering of amino acids in 
nascently synthesized proteins (Mubeen et al. 2018). Thus, 
it is permissible that the inhibitory effect of rapamycin on 
2-deoxyglucose uptake is the result of increased intracellu-
lar leucine concentrations as opposed to impaired mTORc1 
function per se. To discount this possibility, the non-metab-
olizable analogue of l-leucine, BCH, was used to inhibit cel-
lular leucine uptake via competing for the LAT1 transporter. 
Given leucine’s key role in mediating increased mTORc1 
activity in response to amino acid provision (Wolfson et al. 
2016), acute BCH administration represents an alternative 
strategy to reduce mTORc1 function without increasing leu-
cine concentrations. Notably, when comparing the effect of 
Fig. 1  Rapamycin inhibits mTORc1 signalling and 2-deoxyglucose 
(2-DG) uptake in L6 myotubes under both insulin- and non-insulin-
stimulated conditions. 2-DG uptake (a) in response to 1 mM insulin, 
administered for 1 h. Impact of 1 h pre-treatment with 100 nM rapa-
mycin on the phosphorylation state of mTOR (b), 4E-BP1 (c), and 
p70S6K (d) in the presence or absence of 1  mM insulin (n = 3 per 
group). e Impact of 1 and 4 h pre-treatment with 100 nM rapamycin 
on 2-DG uptake in the presence or absence of 1 mM insulin (n = 6 per 
group). f Representative western blot images. *p < 0.05; ***p < 0.001 
significantly different from respective control. ‡‡‡p < 0.001 signifi-
cantly different from non-insulin treated group. b–e Post hoc tests 
were performed only when a significant interaction between terms 
was observed (p < 0.05); otherwise, results for main effects are 
reported. Data are presented as means ± SEM. Con control, Rap rapa-
mycin
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4 h treatment of 100 nM rapamycin with 25 mM BCH, only 
the former affected intracellular-free BCAA concentrations, 
where a 78% increase was observed (p < 0.001; Fig. 2a).
To confirm that BCH does indeed inhibit mTORc1 activ-
ity, L6 myotubes were incubated for 4 h with either 100 nM 
rapamycin or 25 mM BCH, prior to 1 h treatment with or 
without insulin. Utilizing this approach, the phosphorylation 
state of mTOR, 4E-BP1, and p70S6K was suppressed with 
use of either inhibitor, both under insulin- and non-insulin-
stimulated conditions (Fig. 2b–d and g). However, with the 
exception of 4E-BP1, the suppressive effect of rapamycin on 
mTORc1 signalling was greater than that of BCH. Despite 
this, BCH administration suppressed 2-deoxyglucose uptake 
to a greater degree than that of rapamycin, with BCH sup-
pressing uptake of the glucose analogue below basal levels 
and fully preventing the stimulatory effects of insulin on 
2-deoxyglucose uptake (Fig. 2e). Collectively, these findings 
suggest that the inhibitory effect of BCH on 2-deoxyglucose 
uptake occurs, at least in part, through a mechanism inde-
pendent of mTORc1. To ascertain whether this could be 
due to inhibition of AKT phosphorylation, a key mediator 
of insulin-mediated GLUT4 translocation, the phosphoryla-
tion state of AKT Ser473 was examined. Neither rapamycin 
nor BCH administration affected the stimulatory effect of 
insulin on AKT phosphorylation (Fig. 2f), suggesting that 
the detrimental impact of BCH on glucose uptake was not 
mediated by a change in AKT activity.
Leucine availability modulates glucose uptake 
in L6 myotubes, independent of mTORc1 and AKT 
signalling
To determine whether leucine availability impacted on glu-
cose uptake, L6 myotubes were subjected to different leucine 
concentrations (0.0–0.8 mM) for a period of 24 h, and the 
impact on mTORc1 signalling and 2-deoxyglucose uptake 
in the presence and absence of insulin assessed.
Under the conditions studied, modulating leucine avail-
ability had no impact on the phosphorylation state of vari-
ous mTORc1 signalling proteins under either basal or insu-
lin-stimulated conditions (Fig. 3a–c and f). Similarly, the 
phosphorylation state of AKT was unaffected by decreasing 
leucine media concentrations (Fig. 3e). While modulating 
media leucine concentrations had no measurable effect on 
the AKT-mTORc1 signalling axis, there was a significant 
impact on 2-deoxyglucose uptake (Fig. 3d). In the absence 
of insulin, a dose-dependent increase in glucose uptake 
with media leucine concentrations was observed. Moreo-
ver, the ability of insulin to stimulate 2-deoxyglucose uptake 
appeared impaired by leucine deprivation.
Fig. 2  BCH decreases mTORc1 signalling and completely blunts 
the ability of insulin to stimulate 2-deoxyglucose (2-DG) uptake in 
L6 myoblasts, in an AKT-independent manner. Impact of 4  h pre-
treatment with 100  nM rapamycin or 25  mM BCH on intracellular 
concentrations of free branched chain amino acids (BCAA; a). Effect 
of the same treatments on the phosphorylation state of mTORc1 sig-
nalling components (b–d) and AKT (f) in the presence or absence 
of 1  mM insulin (n = 3 per group). e Impact of rapamycin or BCH 
pre-treatment on insulin- and non-insulin-stimulated 2-DG uptake 
(n = 6 per group). g Representative western blot images. *p < 0.05; 
**p < 0.01; ***p < 0.001, significantly different from respective con-
trol. †p < 0.05; †††p < 0.001, significantly different from rapamycin. 
Data are presented as means ± SEM. BCH b(-)2-amino-bicyclo[2,2,1]
heptane-2-carbocyclic acid, Con control, DMEM Dulbecco’s modi-
fied eagle medium, Rap rapamycin
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3BDO reduced mTOR phosphorylation, leading 
to an enhancement of 2‑deoxyglucose uptake 
in the absence of insulin
Given that chronic mTORc1 activation has been proposed as 
a contributor to impaired muscle glucose uptake in insulin-
resistant individuals (Newgard et al. 2009), we wanted to 
investigate what impact mTORc1 hyperactivation had on 
the ability of insulin to stimulate 2-deoxyglucose uptake in 
myotubes. The compound 3BDO has been described as a 
potent mTORc1 activator, and its effectiveness confirmed 
in a number of cell types (Ge et al. 2014; Peng et al. 2014; 
Sheng et al. 2017; Wang et al. 2016). Thus, utilizing 3BDO 
represented a unique pharmacological approach to assess 
mTORc1 activity on glucose uptake in muscle cells.
L6 myotubes were exposed for 4 h to either 100 nM 
rapamycin or 60 μM of the mTORc1 activator to confirm 
the effect of mTORc1 hyperactivity on insulin-stimulated 
glucose uptake. Contrary to expectations, 3BDO decreased 
the phosphorylation of mTOR and p70S6K in the absence 
of insulin compared to control (Fig. 4a–c and f; p < 0.001). 
Similarly, the phosphorylation state of 4E-BP1 and P70S6K 
in response to insulin was below that seen with control when 
treated with 3BDO. In spite of mTORc1 signalling being 
impaired by 3BDO treament, the compound significantly 
increased 2-deoxyglucose uptake in the absence of insulin 
(p < 0.001); albeit, this effect was reversed when exam-
ined under insulin-stimulated conditions (Fig. 4d). While 
a discord in the ability of 3BDO to stimulate 2-deoxyglu-
cose under insulin- and non-insulin-stimulated conditions 
was readily apparent, the mTORc1 activator significantly 
increased the phosphorylation status of AKT compared to 
control, irrespective of insulin administration (p < 0.001; 
Fig.  4e). Unexpectadly, a modest, albeit significant 
(p  < 0.05) increase in AKT phoshorylation status was also 
observed with rapamycin treatment under insulin-stimulated 
conditions.
Discussion
A definitive role for obesity-induced hyperleucinaemia in the 
induction of type-2 diabetes has remained controversial, due 
in part to inconsistent reports on the impact of leucine on 
insulin-stimulated glucose uptake in skeletal muscle. To pro-
vide much needed clarity on the role of leucine in regulating 
glucose uptake in muscle cells, we have examined the impact 
of modifying leucine availability and mTORc1 function on 
Fig. 3  Modest changes in leucine availability affect 2-deoxyglucose 
(2-DG) uptake in L6 myotubes under both insulin- and non-insulin-
stimulated conditions, and occurs in the absence of changes in AKT-
mTORc1 signalling. Impact of 24 h treatment with various concentra-
tions of leucine on the phosphorylation state of mTORc1 signalling 
components (a–c) and AKT (e) in the presence or absence of 1 mM 
insulin (n = 3 per group). d Impact of leucine media concentra-
tions on insulin- and non-insulin-stimulated 2-DG uptake (n = 6 per 
group). f Representative western blot images. *p < 0.05; **p < 0.01; 
***p < 0.001, significantly different from 0  mM leucine treatment. 
†††p < 0.001, significantly different from 0.4 mM leucine treatment. 
Data are presented as means ± SEM. DMEM Dulbecco’s modified 
eagle medium
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insulin-stimulated glucose uptake in myotubes. Utilizing this 
approach, we demonstrate that leucine availability appears 
to play an essential role in glucose uptake in L6 myotubes, 
irrespective of insulin provision. Moreover, we show that 
leucine’s ability to modulate glucose uptake can occur inde-
pendent of changes in mTORc1 signalling status. Finally, we 
demonstrate that the mTORc1 activator, 3BDO, can modu-
late muscle cell glucose uptake, potentially representing an 
interesting pharmacological strategy to enhance non-insulin 
dependent glucose uptake in insulin resistant states.
While the impact of exogenous leucine on muscle glu-
cose uptake has been widely investigated, a consensus on 
its main effects has yet to be reached. Indeed, while numer-
ous studies have demonstrated that leucine administration 
impairs the ability of insulin to stimulate glucose uptake and 
worsens glucose tolerance in animals (Balage et al. 2011; 
Deshmukh et al. 2009; Iwanaka et al. 2010; Moghei et al. 
2016; Saha et al. 2010), this is far from universally observed. 
Rats administered a diet for 5 weeks containing 15% protein 
supplemented with 4.5% leucine have been shown to expe-
rience a significant increase in insulin-stimulated glucose 
transport in epitrochlearis muscle when assessed ex vivo 
(Balage et al. 2011). Notably, this is in spite of an overall fall 
in whole-body insulin sensitivity as determined by oral glu-
cose tolerance test. Similarly, application of media contain-
ing high leucine concentrations (5–10 mM) has been shown 
to result in significant increases in 2-deoxyglucose uptake 
in C2C12 myotubes, even in the absence of insulin (Doi 
et al. 2003). In contrast, others have shown that the ability 
of leucine to facilitate glucose uptake in myotubes derived 
from rat primary skeletal muscle cells occurs only when 
co-administered with insulin (Liu et al. 2014). While our 
findings are unable to definitely address these contradictory 
reports, they provide further support for leucine playing an 
important role in glucose uptake in muscle cells, under both 
insulin- and non-insulin-stimulated conditions. Utilizing 
various approaches to either suppress leucine extracellular 
availability, intracellular import, or leucine-regulated signal-
ling mechanisms, 2-deoxyglucose uptake was consistently 
blunted irrespective of insulin administration, underpinning 
its crucial and direct role in regulating muscle cell glucose 
metabolism. Moreover, by employing techniques that have 
allowed mTORc1 activity and leucine availability to be 
manipulated in isolation of each other, we demonstrate that 
leucine and mTORc1 act independently to regulate 2-deoxy-
glucose uptake in muscle cells.
The notion that leucine plays a permissive role in the 
uptake of glucose in muscle cells has important implications 
concerning the development of approaches to treat type-2 
diabetes. Growing emphasis has been placed on the concept 
of manipulating branched chain amino acids in the diet to 
improve insulin sensitivity in at risk populations (Xiao et al. 
Fig. 4  Treatment with the mTORc1 activator 3BDO inhibits 
components of mTORc1 signalling, but has opposing effects on 
2-deoxyglucose (2-DG) uptake dependent on the presence of insu-
lin. Impact of 4  h pre-treatment with either 100  nM rapamycin or 
60  µM 3BDO on the phosphorylation state of mTORc1 signalling 
components (a–c) and AKT (e) in the presence or absence of 1 mM 
insulin (n = 3 per group). d Impact of rapamycin or 3BDO pre-treat-
ment on insulin- and non-insulin-stimulated 2-DG uptake (n = 6 per 
group). f Representative western blot images. *p < 0.05; **p < 0.01; 
***p < 0.001, significantly different from respective control. 
†p < 0.05; †††p < 0.001, significantly different from rapamycin. Data 
are presented as means ± SEM. 3BDO 3-Benzyl-5-((2-nitrophenoxy)
methyl)-dihydrofuran-2(3H)-one, Con control, DMEM Dulbecco’s 
modified eagle medium, Rap rapamycin
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2011). While leucine deprivation has been found to improve 
muscle insulin signalling in rodents (Xiao et al. 2011), the 
ability of the approach to increase muscle insulin sensitivity 
remains uncertain. Utilizing a leucine analogue as a com-
petitive inhibitor for leucine, thereby limiting cellular uptake 
of the amino acid via its transporter, we demonstrate that 
leucine import likely plays a crucial process in driving insu-
lin-stimulated glucose uptake. While the exact mechanism 
by which this occurs is unclear, it is not without precedent. 
Muscle-specific knockout of the LAT1 transporter in mice 
has been shown to impair whole-body glucose uptake in 
response to a glucose challenge (Poncet et al. 2014). Moreo-
ver, the authors’ demonstration of the importance of LAT1 
in the activation of muscle mTORc1 signalling by exogenous 
leucine viewed in conjunction with our findings that rapamy-
cin blunts glucose uptake in muscle cells, which highlights 
one possible mechanism by which dietary leucine opposes 
the development of insulin resistance in muscle.
While, in the current study, the inhibitory action of 
rapamycin on glucose uptake was consistently observed 
and occurred independent of insulin administration, others 
have argued that any impact of leucine on muscle glucose 
uptake occurs in a purely mTORc1 independent manner. 
In isolated rodent muscle, pre-treatment with rapamycin 
was unable to prevent the stimulatory effects of leucine on 
2-deoxyglucose uptake, albeit the same study failed to dem-
onstrate that mTORc1 was inhibited by rapamycin at the 
dose used, questioning the validity of their findings (Nishi-
tani et al. 2002). In contrast, and in full agreement with the 
data which we present, others have shown that rapamycin 
blocks the beneficial effect of leucine on insulin-stimulated 
glucose uptake in rat primary skeletal muscle cells (Liu et al. 
2014). Similarly, when alternative inhibition strategies have 
been investigated aimed at blocking the action of PI3K, a 
kinase upstream of mTORc1 in canonical pathways, insu-
lin-stimulated glucose uptake in cultured muscle cells was 
impaired (Liu et al. 2014). Moreover, this effect was partially 
rescued by leucine administration, demonstrating that insulin 
and leucine’s beneficial impact on glucose uptake occurs 
via different mechanisms. In support of this notion, whilst 
we observed that AKT phosphorylation was significantly 
increased in response to insulin administration, this was not 
blunted by declining leucine media concentrations or the 
administration of either rapamycin or BCH.
Curiously, while leucine availability is widely acknowl-
edged as a potent activator or mTORc1 signalling, at the 
concentrations studied in the current report (0.0–0.8 mM), 
modulating leucine media concentrations failed to impact the 
examined components of mTORc1 signalling. We believe 
that there are two plausible explanations for this observa-
tion. First, in the previous studies designed to elicit increased 
mTORc1 signalling activity, higher media concentrations 
of leucine were typically utilized (~ 2 to 5 mM). Thus, it 
is permissible that the maximum concentration used in the 
current study (0.8 mM), which is equivalent to the concen-
tration of leucine found in DMEM, was insufficient to stimu-
late mTORc1 activity. Conversely, the ability of leucine to 
stimulate mTORc1 activity has been shown to be transient, 
returning to basal levels despite leucine availability remain-
ing elevated (Gran and Cameron-Smith 2011). Therefore, 
it is possible that at the timepoint examined (24 h), any 
increase in mTORc1 signalling had been missed. Regard-
less of the underlying cause for the lack of observed effect 
of leucine on mTORc1 signalling, our data demonstrate the 
crucial role that leucine availability plays in cellular glucose 
uptake in muscle cells, under both insulin- and non-insulin-
stimulated conditions.
While our data robustly demonstrate that leucine mediates 
glucose uptake in skeletal muscle cells, this does not pre-
clude the possibility that excess leucine also indirectly mod-
ulates peripheral insulin sensitivity in mammals. Increased 
blood leucine concentrations have been associated with 
satiety (Cota et al. 2006; Lynch et al. 2006) and increased 
energy expenditure (Zhang et al. 2007), the latter likely due 
to its potent effects at stimulating tissue protein synthesis, an 
energy intensive process. Indeed, doubling dietary leucine 
intake in mice has been associated with decreasing adiposity 
in diet-induced obese animals while improving whole-body 
insulin sensitivity (Zhang et al. 2007). Given the widely 
described role of adiposity in the development of insulin 
resistance, leucine could be exerting effects in an indirect 
manner. Likewise, the possibility that metabolites of leucine 
or amino acids other than leucine contribute to perturbed 
glucose uptake upon exogenous leucine administration can-
not be excluded. It is widely acknowledged that the bolus 
administration of leucine results in increased formation of 
leucine metabolites (Lee et al. 2015) and a reciprocal fall in 
plasma concentrations of the other branched chain amino 
acids (Matsumoto et al. 2014). Notably, both the leucine 
metabolite α-ketoisocaproate and the branched chain amino 
acid isoleucine have been shown to stimulate increased glu-
cose uptake in muscle (Doi et al. 2007; Nishitani et al. 2002) 
and cultured myotubes (Doi et al. 2003). Crucially, utilizing 
cultured cells, we circumvented the issues associated with 
the impact of leucine on distal tissues and systems, and by 
applying a multipronged approach to modulate leucine trans-
port and availability, we demonstrated that the amino acid 
exerts a direct effect on glucose uptake in muscle cells, albeit 
the lack of a direct measure of intracellular free leucine con-
centrations is a limitation of the current study.
While our findings arguably suggest that leucine admin-
istration could offer beneficial effects by improving insulin 
sensitivity via increasing insulin-dependent muscle glu-
cose uptake, trials of chronic leucine supplementation in 
type-2 diabetic men have proved disappointing to date. A 
study examining the consumption of 7.5 g/day of leucine 
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for 6 months taken in addition to the subject’s habitual diet 
failed to show any metabolic or anthropometric benefit to 
diabetic patients, with insulin sensitivity, as determined by 
oral glucose tolerance test, unaffected by the intervention 
(Leenders et al. 2011). Although leucine supplementation 
may ultimately prove to be an ineffective treatment strat-
egy, our data revealed that targeting the mTORc1 signal-
ling pathway remains judicious. In particular, we observed 
that the mTORc1 activator, 3BDO, has a profound abil-
ity to increase glucose uptake in a non-insulin-dependent 
manner. Contrary to expectations, the beneficial effects of 
3BDO did not appear due to increased mTORc1 signal-
ling, suggesting that its effects occur via alternative mech-
anisms. Indeed, in L6 myotubes, 3BDO appeared to inhibit 
the phosphorylation of mTORc1 and its downstream tar-
gets despite the administration of a dose of 3BDO known 
to increase mTORc1 activity in other cell types (Ge et al. 
2014). Whether this is a response specific to muscle cells, 
the dose utilized, or the timepoint examined is unclear, but 
regardless, our data suggest that the 3BDO compound is 
worthy of further investigation, particularly in the quest for 
strategies to aid glucose homeostasis in diabetic patients.
Conclusions
In summary, results from this study demonstrate that there 
is a relationship between mTORc1 activity and glucose 
uptake in L6 myotubes, but this appears independent of the 
phosphorylation status of AKT. Similarly, while leucine 
promotes basal and insulin-induced glucose uptake in L6 
myotubes, this occurs independent of AKT-mTORc1 sig-
nalling. Collectively, our findings reinforce the direct role 
that leucine plays in the regulation of muscle carbohydrate 
metabolism and suggests that strategies aimed at reducing 
obesity-induced hyperleucinaemia to improve peripheral 
insulin sensitivity could be counterproductive. However, 
the exact mechanism by which leucine exerts its effects 
on glucose uptake in muscle cells remains unknown and 
should be the focus of future work.
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